Biotechnology (53) | Transition Agreements (53)

Browse by Company

Recent Contracts

Transition Agreement and Release, dated as of August 14, 2022, by and between Cara Cassino, M.D. and ContraFect Corporation (CONTRAFECT Corp, Filed With SEC on August 16, 2022)
Amendment to the Transition Services Agreement, by and between 2seventy bio, Inc. and the Registrant (bluebird bio, Inc., Filed With SEC on August 4, 2022)
Transition Agreement dated July 26, 2022, by and between Praxis Precision Medicines, Inc. and Bernard Ravina (Praxis Precision Medicines, Inc., Filed With SEC on July 26, 2022)
Transition Services Agreement, dated as of (VICAL INC, Filed With SEC on May 3, 2022)
Transition Agreement, dated March 28, 2022, between the Company and Michael G. Kauffman (Karyopharm Therapeutics Inc., Filed With SEC on March 29, 2022)
Transition Agreement, dated March 28, 2022, between the Company and Sharon Shacham (Karyopharm Therapeutics Inc., Filed With SEC on March 29, 2022)
Transition Agreement and Release dated March 22, 2022 between the Company and Mark Kowalski (Sierra Oncology, Inc., Filed With SEC on March 23, 2022)
Transition Agreement and Release between the Registrant and David Hilbert, Ph.D., dated January 7, 2022 (Arcellx, Inc., Filed With SEC on January 14, 2022)
Transition Agreement, by and between the Registrant and Richard A. Fisher, dated November 17, 2021 (Vigil Neuroscience, Inc., Filed With SEC on November 19, 2021)
Executive Transition Services Agreement (Aptevo Therapeutics Inc., Filed With SEC on November 12, 2021)